Zydus Lifesciences Ltd.

Financial

	Zydus Lifesciences	Lupin	Torrent Pharma
Operational Metrics
API Sector
US DMF Filings	135.0 .	155.0 .	n/a
Pharmaceutical Sector
Number of ANDA's Filed in USA	460.0 .	447.0 .	166.0 .
Number of ANDA's Approved By USFDA	394.0 .	319.0 .	120.0 .
Domestic Sales Growth - YoY	5.2 %	6.6 %	11.1 %
R&D as a % of Total Sales	7.0 %	7.0 %	5.0 %
Financials
5 yr Average ROE	16.63 %	0.39 %	17.02 %
5yr average Equity Multiplier	1.82	1.85	2.5
5yr Average Asset Turnover Ratio	0.62	0.66	0.61
5yr Avg Net Profit Margin	15.64 %	0.74 %	11.26 %
Price to Book	5.31	5.67	13.49
P/E	33.43	41.93	60.57
5yr Avg Cash Conversion Cycle	-65.67 Days	-27.27 Days	-151.22 Days
Inventory Days	51.98 Days	51.43 Days	54.43 Days
Days Receivable	41.75 Days	56.09 Days	39.91 Days
Days Payable	168.09 Days	155.83 Days	337.02 Days
5yr Average Interest Coverage Ratio	15.34	3.33	4.68
5yr Avg ROCE	16.69 %	6.39 %	21.27 %
5yr Avg Operating Profit Margin	23.13 %	13.98 %	29.61 %
5 yr average Debt to Equity	0.44	0.43	0.97
5yr CAGR Net Profit	1.18 %	-6.65 %	23.34 %
5yr Average Return on Assets	9.5 %	0.23 %	6.93 %
Shareholdings
Promoter Holding	74.98 %	47.01 %	71.25 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.1 %	0.15 %	0.0
Change in Mutual Fund Holding (3 Yrs)	0.3 %	3.77 %	-2.01 %

Business

	Zydus Lifesciences	Lupin	Torrent Pharma
Product Wise Break-Up	Product Wise Break-Up US Formulations 43.0 India Formulations 33.0 Emerging Markets 11.0 Wellness 9.0 Active Pharmaceutical Ingredient (API) 3.0 Alliance 1.0 Europe Formulatios 0 Animal Health 0 EMB Formulations 0 USA 0 Developed Markets 0 NCE licensing income 0 India 0 Emerging Market Formulation 0 Advanced Markets Formulations 0 Generic FDF 0 Custom Synthesis 0 Domestic formulations 0 Contract Manf. 0 Brazil/Latam 0 Germany/Europe 0	Product Wise Break-Up Custom Synthesis 0 Brazil/Latam 0 Wellness 0 NCD 1.0 India Formulations 0 Active Pharmaceutical Ingredient (API) 0 Alliance 0 Developed Markets 0 Germany/Europe 0 Emerging Market 12.0 USA 0 Domestic formulations 0 Generic FDF 0 Contract Manf. 0 US Formulations 0 Emerging Markets 0 EMB Formulations 0 Animal Health 0 India 34.0 Europe Formulatios 0 Advanced Markets Formulations 45.0 Others 8.0	Product Wise Break-Up Custom Synthesis 0 Brazil 8.98 Wellness 0 NCE licensing income 0 India Formulations 0 Active Pharmaceutical Ingredient (API) 0 Alliance 0 Developed Markets 0 Germany 13.15 Emerging Market Formulation 0 USA 0 Domestic Formulations 42.15 Generic FDF 0 Contract Manufacturing 6.15 US Formulations 20.71 Emerging Markets 0 EMB Formulations 0 Animal Health 0 India 0 Europe Formulatios 0 Advanced Markets Formulations 0 Others 8.86
Segment Break-Up	Segment Break-Up Pharmaceuticals 91.12 OTC 8.88 Research Services & Sale of IP`s 0	Segment Break-Up Pharmaceuticals 100.0 Research Services & Sale of IP`s 0 OTC 0	-
Location Wise Break-Up	Location Wise Break-Up India 44.32 USA 43.43 API 0 EMEA 0 Growth Markets 0 Japan 0 Germany 0 Brazil 0 Others 12.25	Location Wise Break-Up USA 37.0 Developed Markets 9.0 API 6.0 EMEA 10.0 Brazil 0 India 34.0 Japan 0 Germany 0 Others 4.0	Location Wise Break-Up USA 10.03 Growth Markets 0 API 0 EMEA 0 Brazil 11.42 India 51.79 Japan 0 Germany 9.88 Others 16.88
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 99.6 OTC 0.4	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Cardiac Science 15.0 Respiratory Systems 14.0 Anti-Infective 12.0 Gastro Intestinal 10.0 Pain Management 8.0 Gynecology 7.0 Dermatology 6.0 Gynae 0 Anti-infective 0 Pain 0 Anti- diabetic 0 CNS 0 Gastro-intestinal 0 Rest 0 VMN 0 Others 28.0	-	Therapeutic Area Break-Up Anti-Infective 3.0 Gastro Intestinal 17.0 Gastro Intestinal 0 CNS 15.0 Anti-Infective 0 Cardiac Science 0 Gynecology 2.0 Gynecology 0 Respiratory Systems 0 Anti - Diabetes 9.0 Pain Management 0 Pain Management 6.0 Rest 2.0 Dermatology 0 VMN 12.0 Others 34.0
Asset Break-Up	Asset Break-Up USA 93.14 India 2.8 Others 4.06	-	Asset Break-Up USA 0.32 India 97.47 Others 2.21

Zydus Lifesciences Ltd.

SIGN UP FOR FREE